664 related articles for article (PubMed ID: 15162466)
1. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
Liu CL; Fan ST; Lo CM; Chan SC; Ng IO; Lai CL; Wong J
Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
[TBL] [Abstract][Full Text] [Related]
2. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber LW; Gaber AO
Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
[TBL] [Abstract][Full Text] [Related]
3. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
4. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.
Washburn K; Speeg KV; Esterl R; Cigarroa F; Pollack M; Tourtellot C; Maxwell P; Halff G
Transplantation; 2001 Nov; 72(10):1675-9. PubMed ID: 11726831
[TBL] [Abstract][Full Text] [Related]
5. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
[TBL] [Abstract][Full Text] [Related]
7. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes.
Humar A; Crotteau S; Gruessner A; Kandaswamy R; Gruessner R; Payne W; Lake J
Clin Transplant; 2007; 21(4):526-31. PubMed ID: 17645714
[TBL] [Abstract][Full Text] [Related]
8. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience.
Aw MM; Taylor RM; Verma A; Parke A; Baker AJ; Hadzic D; Muiesan P; Rela M; Heaton ND; Mieli-Vergani G; Dhawan A
Transplantation; 2003 Mar; 75(6):796-9. PubMed ID: 12660504
[TBL] [Abstract][Full Text] [Related]
9. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months.
Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
Transplant Proc; 2006 Dec; 38(10):3633-5. PubMed ID: 17175352
[TBL] [Abstract][Full Text] [Related]
10. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
Nematalla AH; Bakr MA; Gheith OA; Elagroudy AE; Elshahawy el-M; Aghoneim M
Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
[TBL] [Abstract][Full Text] [Related]
11. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation.
Gruttadauria S; Vasta F; Mandalà L; Cintorino D; Piazza T; Spada M; Verzaro R; Gridelli B
Transplant Proc; 2005; 37(6):2611-3. PubMed ID: 16182762
[TBL] [Abstract][Full Text] [Related]
12. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
Boillot O; Mayer DA; Boudjema K; Salizzoni M; Gridelli B; Filipponi F; Trunecka P; Krawczyk M; Clavien PA; Ducerf C; Margarit C; Margreiter R; Pallardo JM; Hoeckerstedt K; Pageaux GP
Liver Transpl; 2005 Jan; 11(1):61-7. PubMed ID: 15690537
[TBL] [Abstract][Full Text] [Related]
14. Steroid avoidance reduce the cost of morbidities after live-donor renal allotransplants: a prospective, randomized, controlled study.
Gheith OA; Nematalla AH; Bakr MA; Refaie A; Shokeir AA; Ghoneim MA
Exp Clin Transplant; 2011 Apr; 9(2):121-7. PubMed ID: 21453230
[TBL] [Abstract][Full Text] [Related]
15. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.
Becker T; Foltys D; Bilbao I; D'Amico D; Colledan M; Bernardos A; Beckebaum S; Isoniemi H; Pirenne J; Jaray J;
Transplantation; 2008 Dec; 86(12):1689-94. PubMed ID: 19104406
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.
Orr DW; Portmann BC; Knisely AS; Stoll S; Rela M; Muiesan P; Bowles MJ; Heaton ND; O'Grady JG; Heneghan MA
Transplant Proc; 2005 Dec; 37(10):4373-9. PubMed ID: 16387124
[TBL] [Abstract][Full Text] [Related]
17. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation.
Lin CC; Chuang FR; Lee CH; Wang CC; Chen YS; Liu YW; Jawan B; Chen CL
Liver Transpl; 2005 Oct; 11(10):1258-64. PubMed ID: 16184544
[TBL] [Abstract][Full Text] [Related]
18. Initial immunosuppression with or without basiliximab: a comparative study.
Martín-Mateos RM; Graus J; Albillos A; Arocena C; Rodríguez Gandía MA; Blesa C; García-Hoz F; García González M; García-Alonso FJ; Bárcena R
Transplant Proc; 2012 Nov; 44(9):2570-2. PubMed ID: 23146457
[TBL] [Abstract][Full Text] [Related]
19. Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients.
Cuervas-Mons V; Herrero JI; Gomez MA; González-Pinto I; Serrano T; de la Mata M; Fabregat J; Gastaca M; Bilbao I; Varo E; Sánchez-Antolín G; Rodrigo J; Espinosa MD
Clin Transplant; 2015 Aug; 29(8):667-77. PubMed ID: 25924549
[TBL] [Abstract][Full Text] [Related]
20. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction.
Jain A; Sharma R; Ryan C; Tsoulfas G; Orloff M; Abt P; Kashyap R; Batzold P; Sauberman L; Safadjou S; Graham M; Bozorgzadeh A
Liver Transpl; 2008 Feb; 14(2):202-9. PubMed ID: 18236395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
